Full Press Release Details
Pharmaceuticals to Host Lupus Nephritis Opinion Leader Meeting
Webcast on May 5 in New York
VICTORIA, British Columbia--(BUSINESS WIRE)--April 23, 2015--Aurinia
Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) today announced it will host
a Lupus Key Opinion Leader breakfast on Tuesday, May 5 from 8:00 to 9:30
The topic of the meeting will be: Lupus Nephritis: Are early
markers predictive of long-term outcomes? and will feature
David Wofsy, M.D., Professor of Medicine and Microbiology/Immunology at
the University of California San Francisco. He also serves as Associate
Dean for Admissions at the UCSF School of Medicine. Dr. Wofsy's research
career has been devoted to the development of novel therapies for
systemic lupus erythematosus (SLE), first through studies in murine
models and more recently through the conduct of clinical trials. In
addition to his studies of novel approaches to the treatment of SLE, Dr.
Wofsy has been a leader in identifying early clinical predictors of
long-term outcome in patients with lupus nephritis. Dr. Wofsy received
his M.D. from the University of California San Diego and subsequently
underwent internal medicine residency and rheumatology fellowship
training at UCSF. He has been Chief of the Division of Rheumatology at
the San Francisco VA Medical Center and Director of the Dept. of
Medicine Clinical Trials Center at UCSF. Dr. Wofsy also served as
President of the American College of Rheumatology (2003-04).
Dr. Neil Solomons, Aurinia's Chief Medical Officer will also provide a
brief overview and details of the company's ongoing lupus nephritis
A live webcast of the event will be available at: http://lifesci.rampard.com/20150505
and on the Investors section of the Company's website at http://www.auriniapharma.com/dnn/ForInvestors.aspx.
The event is intended for qualified institutional investors and
sell-side analysts. To attend please contact Mac MacDonald: 212-915-2567
Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is
currently enrolling patients in its Phase 2b clinical trial to evaluate
the efficacy of its drug, voclosporin, as a treatment for LN. LN is an
inflammation of the kidneys, that if inadequately treated can lead to
end-stage renal disease, making LN a serious and potentially
life-threatening condition. Voclosporin is a novel and potentially best
in class calcineurin inhibitor (CNI) with extensive clinical data in
more than 2,600 patients in other indications. Voclosporin is made by a
modification of a single amino acid of the cyclosporine molecule (a CNI
approved for use in transplant patients since 1983). This modification
results in a more predictable pharmacokinetic and pharmacodynamic
relationship, an increase in potency vs. cyclosporine, an altered
metabolic profile, and potential for flat dosing. Aurinia also has
development and commercialization partners in Canada, Israel, South
Africa and Greater China.We seek Safe Harbor.
Aurinia Pharmaceuticals Inc.
Stephen Zaruby, 250-708-4293
& Chief Executive Officer
Michael Martin, 250-708-4272
Chief Operating Officer